Physician profile
Rayna Gorstein
NPI 1639869076
$2,926.13
in general payments reported to CMS, 2019-2025
19 companies · $1,272 in 2025
The $1,272 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $246 · 2024: $1,408 · 2025: $1,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,926.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $853.15 | 2023-2025 | |
| Axsome Therapeutics, INC. | $257.17 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $230.97 | 2024-2025 | Spravato |
| Lundbeck LLC | $230.43 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $225.74 | 2023-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $207.48 | 2024-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $156.99 | 2023-2024 | Jornay Pm |
| Neos Therapeutics, LP | $148.47 | 2023-2025 | Adzenys Xr-Odt, Exxua |
| Supernus Pharmaceuticals, INC. | $135.80 | 2024-2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.83 | 2024-2025 | Caplyta |
| Noven Therapeutics, LLC | $78.28 | 2023-2025 | Xelstrym |
| Vanda Pharmaceuticals INC. | $64.23 | 2024-2025 | Fanapt |
| Collegium Pharmaceutical, INC. | $54.62 | 2025 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $53.78 | 2023-2024 | Rexulti |
| Alkermes, INC. | $41.06 | 2025 | Lybalvi |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $22.67 | 2024 | Loreev Xr |
| Tris Pharma INC | $22.27 | 2025 | Dyanavel Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.00 | 2024 | |
| Tempus Ai, INC | $17.19 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rayna Gorstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.